An ancillary biomarker study in the SAMIT randomized trial: Sequential paclitaxel followed by UFT or S-1 versus UFT or S-1 alone as adjuvant chemotherapy for T4a/b gastric cancer | Zendy

AI Assistant Blog Pricing

An ancillary biomarker study in the SAMIT randomized trial: Sequential paclitaxel followed by UFT or S-1 versus UFT or S-1 alone as adjuvant chemotherapy for T4a/b gastric cancer

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.